Treatment of VTE
Predicting major bleeding during anticoagulation for venous thromboembolism
. Paolo Prandoni, Franca Bilora, Raffaele Pesavento, José María Pedrajas, José Luis Fernández-Reyes, Covadonga Gómez-Cuervo, Aurora Villalobos, Alicia Alda-Lozano, Paolo Simioni, Manuel Monreal; RIETE Investigators. DOAC score for prediction of major bleeding in patients with venous thromboembolism: findings from the RIETE registry. Thromb Res. 2025 Jan:245:109226. doi: 10.1016/j.thromres.2024.109226. Epub 2024 Nov 19.
Enoxaparin versus other LMWHs in cancer-associated venous thromboembolism
. Manuel Monreal, Benjamin Brenner, Covadonga Gómez-Cuervo, Najib Dally, Alicia Alda-Lozano, María Lourdes Pesce, Joaquín Alfonso-Megido, Jacinto Hernández-Borge, Raphael L E Mao, Paolo Prandoni; RIETE Investigators. Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE. Res Pract Thromb Haemost. 2025 Oct 31;9(8):103244. doi: 10.1016/j.rpth.2025.103244. eCollection 2025 Nov.
External validation of the VTE-PREDICT score in clinical practice
. Timothy Hoberstorfer, Stephan Nopp, Daniel Steiner, Luis Hernández-Blasco, Inés Jou, Juan José López-Núñez, Ángeles Fidalgo, Patricia López-Miguel, Manuel Monreal, Cihan Ay; RIETE Investigators. External validation of the VTE-PREDICT score for predicting recurrence and bleeding in venous thromboembolism: results from the Registro Informatizado Enfermedad TromboEmbólica Registry. J Thromb Haemost. 2025 Dec;23(12):3909-3919. doi: 10.1016/j.jtha.2025.08.007. Epub 2025 Aug 22.
Post-discharge venous thromboembolism: a 20-year overview
. Benjamin Brenner, Inna Tzoran, Behnood Bikdeli, Reina Valle, Géraldine Poenou, Raimundo Tirado-Miranda, Maria L. Pesce, Javier Pagán-Escribano, Matteo Giorgi-Pierfranceschi, Manuel Monreal; RIETE Investigators. Venous thromboembolism after hospital discharge: temporal trends in baseline characteristics, prevention, treatment, and 90-day outcomes. Semin Thromb Hemost. 2025 Apr;51(3):301-311. doi: 10.1055/s-0044-1791817. Epub 2024 Oct 17.
Baseline thrombocytopenia as a predictor of early mortality in VTE
. Ramón Lecumberri, Pedro Ruiz-Artacho, Javier Trujillo-Santos, María Marcos-Jubilar, Montserrat Pérez-Pinar, Isabelle Quéré, Gisela Claver, Juan Gorostidi, Behnood Bikdeli, Manuel Monreal; RIETE Investigators. Impact of baseline thrombocytopenia on early outcomes in patients with acute venous thromboembolism. Am J Hematol. 2025 Mar;100(3):375-382. doi: 10.1002/ajh.27579. Epub 2025 Jan 10.
Is the DOAC score effective for bleeding risk prediction in venous thromboembolism?
. Paolo Prandoni, Franca Bilora, Raffaele Pesavento, José María Pedrajas, José Luis Fernández-Reyes, Covadonga Gómez-Cuervo, Aurora Villalobos, Alicia Alda-Lozano, Paolo Simioni, Manuel Monreal; RIETE Investigators. DOAC Score for prediction of major bleeding in patients with venous thromboembolism: findings from the RIETE registry. Thromb Res. 2025 Jan:245:109226. doi: 10.1016/j.thromres.2024.109226. Epub 2024 Nov 19.
Clinical trends in VTE management for patients aged ≥90: insights from the RIETE registry
. Ludovic Lafaie, Géraldine Poenou, Olivier Hanon, Sonia Otálora, Luciano López Jiménez, Aitor Ballaz, Silvia Soler, Manuel Jesús Núñez Fernández, Laurent Bertoletti, Manuel Monreal; RIETE investigators. Venous thromboembolism in patients aged ≥90 years: Trends in clinical features, treatment, and outcomes-RIETE registry. J Am Geriatr Soc. 2024 Dec 3. doi: 10.1111/jgs.19306. Online ahead of print.
New insights into intracranial bleeding risk during anticoagulation for VTE
. Ana Maestre, Mar Martín del Pozo, Farès Moustafa, Romain Chopard, José Antonio Nieto, María Ángeles Fidalgo Fernández, Patricia López Miguel, Peter Verhamme, Maurizio M. Ciammaichella, Manuel Monreal; RIETE investigators. Predicting intracranial bleeding during anticoagulation for venous thromboembolism within different time frames: Findings from the RIETE registry. Thromb Res. 2024 Nov:243:109153. doi: 10.1016/j.thromres.2024.109153. Epub 2024 Sep 13.
Evaluating bleeding risk in VTE patients on DOACs and statins
. Rosaria del Giorno, Lucia Mazzolai, Sanjiv Keller, Carmine Siniscalchi, Luciano López-Jiménez, Aitor Ballaz, Ana Cristina Montenegro, Remedios Otero, Farid Rashidi, Manuel Monreal; RIETE Investigators. Assessment of bleeding events in patients receiving DOACs with or without statins to treat venous thromboembolism: insights from the RIETE registry. BMJ Open. 2024 Oct 22;14(10):e085401. doi: 10.1136/bmjopen-2024-085401.
Inherited thrombophilia, VTE and DOACs
. Omri Cohen, Gili Kenet, Sarina Levy-Mendelovich, Inna Tzoran, Benjamin Brenner, Cristina De Ancos, Patricia López-Miguel, José F. Varona, Judith Catella, Manuel Monreal, RIETE Investigators. Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry. J Thromb Thrombolysis. 2024 Apr;57(4):710-720. doi: 10.1007/s11239-024-02957-4. Epub 2024 Mar 16.
DOACs in obese patients: real life results
. José Antonio Rueda-Camino, Raquel Barba, Sonia Otálora, Alessandra Bura-Rivière, Adriana Visonà, Isabelle Mahé, Alicia Alda-Lozano, Joaquín Alfonso Megido, Nazaret Pacheco-Gómez, Rachel P. Rosovsky, Manuel Monreal and RIETE Investigators. Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism. Thromb Res. 2024 Jan:233:165-172. doi: 10.1016/j.thromres.2023.12.001. Epub 2023 Dec 5.
Anticoagulation in patients aged 90 years
. Ludovic Lafaie, Géraldine Poenou, Olivier Hanon, Luciano López-Jiménez, José Antonio Nieto, Alicia Lorenzo, José Antonio Porras, Marina Lumbierres, Laurent Bertoletti, Manuel Monreal and RIETE Investigators. Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry. J Am Geriatr Soc. 2024 Jan;72(1):113-125. doi: 10.1111/jgs.18626. Epub 2023 Oct 10.
Machine learning to predict major bleeding
. Damián Mora, Jorge Mateo, José A. Nieto, Behnood Bikdeli, Yugo Yamashita, Stefano Barco, David Jiménez, Pablo Demelo-Rodriguez, Vladimir Rosa, Hugo Hyung Bok Yoo, Parham Sadeghipour, Manuel Monreal and RIETE Investigators. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations. Br J Haematol. 2023 Jun;201(5):971-981. doi: 10.1111/bjh.18737. Epub 2023 Mar 21.
Treatment in long-term immobile patients
. Ido Weinberg, Islam Y. Elgendy, Andrew B. Dicks, Pablo J. Marchena, Radovan Malý, Iria Francisco, José M. Pedrajas, Carme Font, Luis Hernández-Blasco, Manuel Monreal and RIETE Investigators. Comparison of Presentation, Treatment, and Outcomes of Venous Thromboembolism in Long-Term Immobile Patients Based on Age. J Gen Intern Med. 2023 Jun;38(8):1877-1886. doi: 10.1007/s11606-023-08058-x. Epub 2023 Feb 7.
Prolong or discontinue anticoagulation beyond the first three month
. Paolo Prandoni, Franca Bilora, Isabelle Mahé, José F. Varona, José María Pedrajas, Jose Meireles, Raffaele Pesavento, Manuel Monreal and RIETE Investigators. The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry. Front Med (Lausanne). Thromb Res. 2023 Apr:224:17-20. doi: 10.1016/j.thromres.2023.02.006. Epub 2023 Feb 14.
Use of DOACs in daily practice
. Alicia Lorenzo, Patricia Beroiz, Salvador Ortiz, Jorge del Toro, Lucia Mazzolai, Alessandra Bura-Rivière, Adriana Visonà, Peter Verhamme, Pierpaolo Di Micco, Giuseppe Camporese, Teresa Sancho Bueso, Manuel Monreal and RIETE Investigators. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry. Front Med (Lausanne). 2022 Nov 25:9:991376. doi: 10.3389/fmed.2022.991376. eCollection 2022.
Combining anticoagulants with antiplatelets
. Paolo Prandoni, Franca Bilora, Raffaele Pesavento, Teresa Sancho, Sandrine Accassat, Ignacio Casado, Pierpaolo Di Micco, Manuel Monreal and RIETE Investigators. The hazard of combining anticoagulants with antiplatelets in patients with venous thromboembolism: Findings from the RIETE registry. Thromb Res. 2022 Oct:218:44-47. doi: 10.1016/j.thromres.2022.08.011. Epub 2022 Aug 13.
Major gastrointestinal bleeding and VTE
. Judith Catella, Laurent Bertoletti, Farès Moustafa, José Antonio Nieto, Reina Valle, José María Pedrajas, Aurora Villalobos, Isabelle Quere, Gabrielle Sarlon-Bartoli, Manuel Monreal and RIETE Investigators. Major gastrointestinal bleeding in patients receiving anticoagulant therapy for venous thromboembolism. Thromb Res. 2022 Jun:214:29-36. doi: 10.1016/j.thromres.2022.04.005. Epub 2022 Apr 13.
Anticoagulation in patients with autoimmune disorders
. Pablo Ruiz-Sada, Lucia Mazzolai, Andrei Braester, Aitor Ballaz, Olga Madridano, Sandrine Accassat, José Luis Fernández-Reyes, Juan Bosco López-Sáez, María del Carmen Díaz-Pedroche, Manuel Monreal, Registro Informatizado de Enfermedad TromboEmbólica (RIETE) Investigators. Venous thromboembolism in patients with autoimmune disorders: a comparison between bleeding complications during anticoagulation and recurrences after its discontinuation. Br J Haematol. 2022 May;197(4):489-496. doi: 10.1111/bjh.18124. Epub 2022 Mar 8.
Full-dose vs moderate-dose
. Ana Jaureguízar, Cassius Iyad Ochoa Chaar, Alfonso Muriel, Jerónimo Ramón Vela Moreno, Ido Weinberg, Antonella Tufano, José F Varona, Behnood Bikdeli, David Jiménez, Manuel Monreal, Registro Informatizado de la Enfermedad Tromboembólica (RIETE) Investigators. Comparison of full-dose vs moderate-dose systemic thrombolysis for the treatment of patients with acute pulmonary embolism. Chest. 2022 Aug;162(2):448-451. doi: 10.1016/j.chest.2022.02.026. Epub 2022 Feb 20.
Liver, anticoagulant therapy and VTE
. Diego Martínez-Urbistondo,Rocío G. de la Garza, Paula Villares-Fernández, Carme Font, Sebastian Schellong, Juan José López-Núñez, Aída Gil-Díaz, María del Carmen Díaz-Pedroche, Jana Hirmerova, Manuel Monreal and The RIETE Investigators, RIETE investigators. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. Intern Emerg Med. 2022 Apr;17(3):725-734. doi: 10.1007/s11739-021-02858-x. Epub 2021 Oct 9.
Comparison of the RIETE and the VTE-BLEED scores
. Ramón Lecumberri, Laura Jiménez, Pedro Ruiz-Artacho, José Antonio Nieto, Nuria Ruiz-Giménez, Adriana Visonà, Andris Skride, Farès Moustafa, Javier Trujillo, Manuel Monreal, RIETE investigators. Prediction of major bleeding in anticoagulated patients for venous thromboembolism: comparison of the RIETE and the VTE-BLEED scores. TH Open. 2021 Aug 9;5(3):e319-e328. doi: 10.1055/s-0041-1729171. eCollection 2021 Jul.
Dose of edoxaban for for the long-term therapy
. Giuseppe Camporese, Paolo Simioni, Pierpaolo Di Micco, Carmen Fernández-Capitán, Agustina Rivas, Carme Font, Joan Carles Sahuquillo, Paula Villares, Paolo Prandoni, Manuel Monreal, RIETE InvestigatorsEdoxaban for the long-term therapy of venous thromboembolism: should the criteria for dose reduction be revised?. Clin Transl Sci. 2021 Jan;14(1):335-342. doi: 10.1111/cts.12876. Epub 2020 Oct 10.
Psychotropic drugs during anticoagulant therapy
. Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Thromb Haemost. 2020 Apr;120(4):620-626. doi: 10.1055/s-0040-1708482.
Rivaroxaban or apixaban?
. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. Thromb Res. 2020 Sep;193:160-165. doi: 10.1016/j.thromres.2020.06.035.
Evaluation of the SAMe-TT2R2 score
. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE Registry. Throm Res. 020 Jun 15;194:178-182. doi: 10.1016/j.thromres. 2020.06.022.
Why patients with proximal lower limb DVT prematurely discontinued anticoagulation?
. Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely. Thromb Res. 2020 May;189:61-68. doi: 10.1016/j.thromres.2020.03.001.
The Charlson score in predicting bleeding
. Predicting the risk for major bleeding in elderly patients with venous thromboembolism using the Charlson index. Findings from the RIETE. J Thromb Thrombolysis. 2020 Sep 18. doi: 10.1007/s11239-020-02274-6.
Severe renal impairment in patients with venous thromboembolism
. Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. J Thromb Haemost. 2020 Jul;18(7):1728-1737. doi: 10.1111/jth.14837.
The more suitable dose of LMWH for obese patients with VTE?
. Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE Registry). Blood Adv. 2020 Jun 9;4(11):2460-2467. doi: 10.1182.
Best anticoagulant therapy in fragile patients with venous thromboembolism?
. Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism. TH Open. 2019 Mar 20;3(1):e67-e76. doi: 10.1055/s-0039-1683970.
Statins in patients with anticoagulant therapy
. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE Registry. Eur J Intern Med. 2019 Oct;68:30-35. doi: 10.1016/j.ejim.2019.07.028.
What happens in patients with acute PE in whom we cannot administer anticoagulants?
. Nieto JA, Vicente JA, Prieto LM, Jiménez D, Bikdeli B, Rivas A, Porras JA, Morales MDV, Bosevski M, Monreal M; RIETE Investigators. Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days. Am Heart J. 2018 Sep 5;206:1-10. doi: 10.1016/j.ahj.2018.08.014.
Outcomes in VTE patients presenting with major bleeding while receiving VKAs for VTE
. Moustafa F, Stehouwer A, Kamphuisen P, Sahuquillo JC, Sampériz Á, Alfonso M, Pace F, Suriñach JM, Blanco-Molina Á, Mismetti P, Monreal M; RIETE Investigators. Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism. Thromb Res. 2018 Sep 22;171:74-80. doi: 10.1016/j.thromres.2018.09.
Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis
. Tufano A, Ageno W, Di Micco P, Niglio A, Rosa V, Ballaz A, Braester A, Rubio CM, Isern V, Imbalzano E, Monreal M; RIETE Investigators. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thromb Res. 2018 Apr;164:69-74. doi: 10.1016/j.thromres.2018.02.143. Epub 2018 Mar 2.
Anticoagulant therapy in patients with inflammatory bowel disease
. Lobo JL, Garcia-Fuertes JA, Trujillo-Santos J, Merah A, Blanco-Molina MÁ, Casado I, Hirmerova J, De Miguel J, Salgado E, Monreal M; RIETE Investigators. Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2018 May;30(5):526-530. doi: 10.1097/MEG.0000000000001084.
Anemia and bleeding in patients receiving anticoagulant therapy
. Kuperman A, López-Reyes R, Bosco LJ, Lorenzo A, José B, Farge Bancel D, Alfonso M, Lumbierres M, Stemer G, Monreal Bosch M, Braester A; RIETE Investigators. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism. J Thromb Thrombolysis. 2018 Apr;45(3):360-368. doi: 10.1007/s11239-018-1610-9.
Real-life use of anticoagulants in patients excluded in clinical trials on direct oral anticoagulants
. Moustafa F, Pesavento R, di Micco P, González-Martínez J, Quintavalla R, Peris ML, Porras JA, Falvo N, Baños P, Monreal M; RIETE Investigators. Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants. Clin Pharmacol Ther. 2018 Apr;103(4):684-691. doi: 10.1002/cpt.781. Epub 2017 Aug 7.
Anticoagulant therapy during hormonal use
. Blanco-Molina Á, Trujillo-Santos J, Pesavento R, Rosa V, Falgá C, Tolosa C, Mazzolai L, Sampériz Á, Duce R, Monreal M; RIETE Investigators. Outcome after discontinuing anticoagulant therapy in women with venous thromboembolism during hormonal use. Thromb Res. 2017 Mar;151 Suppl 1:S6-S10. doi: 10.1016/S0049-3848(17)30059-2.
Uterine bleeding during a VTE therapy
. Moustafa F, Fernández S, Fernández-Capitán C, Nieto JA, Pedrajas JM, Visoná A, Valero B, Marchena PJ, Braester A, Monreal M; RIETE Investigators. Uterine bleeding during anticoagulation in women with venous thromboembolism. Thromb Res. 2017 Mar;151 Suppl 1:S1-S5. doi: 10.1016/S0049-3848(17)30058-0.
Once versus twice daily enoxaparin in initial treatment of VTE
. Trujillo-Santos J, Bergmann JF, Bortoluzzi C, López-Reyes R, Giorgi-Pierfranceschi M, López-Sáez JB, Ferrazzi P, Bascuñana J, Suriñach JM, Monreal M. Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. J Thromb Haemost. 2017 Mar;15(3):429-438. doi: 10.1111/jth.13616. Epub 2017 Feb 18.
Outcomes associated with inferior vena cava filters
. Mellado M, Pijoan JI, Jiménez D, Muriel A, Aujesky D, Bertoletti L, Decousus H, Barrios D, Clará A, Yusen RD, Monreal M; RIETE Investigators. Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy. JACC Cardiovasc Interv. 2016 Dec 12;9(23):2440-2448. doi: 10.1016/j.jcin.2016.08.039. Epub 2016 Nov 9.
Anticoagulant therapy in cancer patients with a pulmonary embolism
. Peris M, Jiménez D, Maestre A, Font C, Tafur AJ, Mazzolai L, Xifre B, Skride A, Dentali F, Monreal M; RIETE Investigators. Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. Eur Respir J. 2016 Nov;48(5):1360-1368. doi: 10.1183/13993003.00779-2016. Epub 2016 Sep 22.
Real-life treatment of venous thromboembolism with direct oral anticoagulants
. Trujillo-Santos J, Di Micco P, Dentali F, Douketis J, Díaz-Peromingo JA, Núñez MJ, Cañas I, Mastroiacovo D, Saraiva de Sousa M, Monreal M; RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost. 2017 Jan 26;117(2):382-389. doi: 10.1160/TH16-07-0494. Epub 2016 Oct 27.
Arterial ischemia after VTE
. Madridano O, Del Toro J, Lorenzo A, Martín M, Gómez Cerezo J, Hernández L, Prandoni P, Monreal M; RIETE Investigators. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. J Vasc Surg Venous Lymphat Disord. 2015 Apr;3(2):135-141.e1. doi: 10.1016/j.jvsv.2014.11.002. Epub 2015 Mar 13.
VTE in patients with negative D-dimer levels
. Soto MJ, Grau E, Gadelha T, Palareti G, Bounameaux H, Villalta J, Monreal M and the RIETE investigators. Clinical significance of negative D-dimer level in patients with confirmed venous thromboembolism. Findings from the RIETE Registry. J Thromb Haemost 2011 Feb; 9(2): 407-10.
Major bleeding and death
. Prandoni P, Trujillo-Santos J, Sánchez-Cantalejo E, Dalla Valle F, Piovella C, Pesavento R, Nieto Rodríguez JA, Monreal M for the RIETE Group. Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2010 Nov; 8(11): 2575-7.
VTE recurrences during therapy
. Lobo JL, Jiménez D, Orue MT, Grau E, Naufall D, Madridano O, Monreal M and the RIETE Investigators. Recurrent venous thromboembolism during coumarin therapy. Data from the computerised Registry of patients with venous thromboembolism. Brit J Haematol 2007 Aug; 138 (3): 400-3.
Platelet count and bleeding during VKA
. Giorgi-Pierfranceschi M, Di Micco P, Cattabiani C, Guida A, Pagán B, Morales MV, Salgado E, Suriñach JM, Tolosa C, Monreal M and the RIETE Investigators. Platelet count and major bleeding in patients receiving vitamin K antagonists for acute venous thromboembolism, Findings from real world clinical practice. Medicine (Baltimore) 2015 Nov; 94(47): e1915.
How do we treat VTE in Italy?
. Dentali F, Di Micco G, Giorgi Pierfranceschi M, Gussoni G, Barillari G, Amitrano M, Fontanella A, Lodigiani C, Guida A, Visonà A, Monreal and Di Micco P. Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. Ann Med 2015 Sep 30: 1-9.
Arterial complications after a VTE
. Madridano O, del Toro J, Lorenzo A, Martin M, Gómez Cerezo J, Prandoni P, Hernández L, Prandoni P, Monreal M, and the RIETE Investigators. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. J Vasc Surg: Venous and Lymphatic Disorders 2015 Apr; 3 (2):135-141.
VTE is often generated at home
. López-Reyes R, Nauffal D, Ballester M, Martín-Antorán JM, de Sousa MS, Riera-Mestre A, Ruiz-Ruiz J, Fernández-Capitán C, Uresandi F, Monreal M and the RIETE Investigators. Venous thromboembolism in patients immobilised at home. Eur Respir J 2015 Jun; 45(6): 1728-31.
How do we treat VTE?
. Mahé I, Sterpu R, Bertoletti L, López-Jiménez L, Mellado Joan M, Trujillo-Santos J, Ballaz A, Hernández Blasco LM, Marchena PJ, Monreal M and the RIETE investigators. Long-Term anticoagulant therapy of patients with venous thromboembolism. What are the practices? PLoS One 2015 Jun 15; 10(6):e0128741.
How long do we treat VTE?
. Ageno W, Sampériz A, Caballero R, Dentali F, Di Micco P, Prandoni P, Becattini C, Uresandi F, Verhamme P, Monreal M and the RIETE investigators. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res 2015 Apr; 135(4): 666-72.
Fondaparinux in the treatment for VTE
. Pesavento R, Amitrano M, Trujillo-Santos J, Di Micco P, López-Jiménez L, Falgá C, García-Bragado F, Piovella C, Prandoni P, Monreal M and the RIETE Investigators. Fondaparinux in the initial and long-term treatment of venous thromboembolism. Thromb Res 2015 Feb; 135(2): 311-7.
Comparison of 4 scales to identify the risk of bleeding
. Piovella C, Dalla Valle F, Trujillo-Santos J, Pesavento R, López L, Font L, Valle R, Nauffal D, Monreal M, Prandoni P and the RIETE Investigators.Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism. Findings from the RIETE Registry. Intern Emerg Med 2014 Dec; 9(8): 847-52.
Antiplatelet drugs and anticoagulation
. Tzoran I, Brenner B, Sakharov G, Trujillo-Santos J, Lorenzo A, Madridano O, López-Sáez JB, Monreal M and RIETE investigators. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy. Eur J Intern Med 2014 Nov; 25(9): 821-5.
Sex differences
. Blanco-Molina A, Enea I, Gadelha T, Tufano A, Bura-Riviere A, Di Micco P, Bounameaux H, González J, Villalta J, Monreal M. Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore). 2014 Oct; 93(17): 309-17.
Platelet count nd outcome
. Di Micco P, Ruiz-Giménez N, Nieto JA, Aujesky D, Del Molino F, Valle R, Barrón M, Maestre A, Monreal M, and the RIETE investigators. Platelet count and outcome in patients with acute venous thromboembolism. Thromb Haemost 2013 Oct; 110(5): 1025-34.
Case-fatality rates of recurrences of bleeding
. Lecumberri R, Alfonso A, Jiménez D, Fernández Capitán C, Prandoni P, Wells PS, Vidal G, Barillari G, Monreal M, and the RIETE Investigators. Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost 2013 Sept; 110(4): 834-43.
Validation of the prognostic score for fatal bleeding
. Nieto JA, Solano R, Trapero Iglesias N, Ruiz-Giménez N, Fernández-Capitán C, Valero B, Tiberio G, Bura-Riviere A, Monreal M for the RIETE Investigators. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thromb Res 2013 Aug; 132(2): 175-9.
VTE in patients with chronic lung disease
. Bertoletti L, Quenet S, Mismetti P, Hernández L, Martín-Villasclaras JJ, Tolosa C, Valdés M, Barrón M, Todolí J, Monreal M and the RIETE Investigators. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J 2012 Apr; 39(4): 862-8.
Fever in patients with VTE
. Barba R, Di Micco P, Blanco-Molina A, Delgado C, Cisneros E, Villalta J, Morales MV, Bura-Riviere A, Debourdeau P, Monreal M, for the RIETE Investigators. Fever and deep venous thrombosis. Findings from the RIETE Registry. Thromb Thrombolysis. 2011 Oct; 32(3): 288-92.
Thrombocytopenia due to heparin
. Falvo N, Bonithon-Kopp C, Rivron-Guillot K, Todolí JA, Jiménez-Gil M, Di Micco P, Monreal M, for the RIETE Investigators. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2011 Sep; 9(9):1761-8.
Mortality on weekends vs. working days
. Lecumberri R, Soler S, del Toro J, Barba R, Rosa V, Ciammaichella M, Monreal M. Effect of the time of diagnosis on outcome in patients with acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2011 Jan; 105(1): 45-51.
In patients vs. out patients
. Maestre A, Sánchez R, Rosa V, Aujesky D, Lorenzo A, Barillari G, Monreal M and the RIETE Investigators. Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism. Findings from the RIETE Registry. Eur J Intern Med 2010 Oct; 21(5): 377-82
Prognostic score for fatal bleeding
. Nieto JA, Solano R, Ruiz-Ribó MD, Ruiz-Giménez N, Prandoni P, Kearon C, Monreal M and the RIETE Investigators. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2010 Jun; 8(6):1216-22.
Recent major bleeding
. Nieto JA, Camara T, González-Higueras E, Ruiz-Giménez N, Guijarro R, Marchena PJ, Monreal M for the RIETE Investigators. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008 Nov; 100(5): 789-96.
Prognostic score for major bleeding
. Ruiz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Sampériz AL, Monreal M and the RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008 Jul; 100(1): 26-31.
Obesity and mortality
. Barba R, Zapatero A, Losa JE, Valdés V, Todolí JA, Di Micco P, Monreal M and the RIETE Investigators. Body mass index and mortality in patients with acute venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2008 Apr; 6(4): 595-600.
VTE in patients with extreme body weight
. Barba R, Marco J, Martín-Álvarez H, Rondón P, Fernández-Capitán C, García-Bragado F, Monreal M for the RIETE Investigators. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective Registry (RIETE). J Thromb Haemost 2005 May; 3(5): 856-62.
Bed rest in initial therapy
. Trujillo-Santos J, Perea-Milla E, Jiménez-Puente A, Sánchez-Cantalejo E, Del Toro J, Grau E, Monreal M and the RIETE Investigators. Bed rest or ambulation in the initial treatment of patients with acute deep vein thrombosis or pulmonary embolism: findings from the RIETE Registry. Chest 2005 May; 127(5): 1631-6.
About us
The RIETE Registry is the world’s largest database on patients with venous thromboembolism (VTE).
RIETE Registry is a Fundación Fuente project
Follow us
Last update
June 2026
RIETE 2018 © 2018 All rights reserved